182 related articles for article (PubMed ID: 35704345)
1. Rivaroxaban Monotherapy vs Combination Therapy With Antiplatelets on Total Thrombotic and Bleeding Events in Atrial Fibrillation With Stable Coronary Artery Disease: A Post Hoc Secondary Analysis of the AFIRE Trial.
Naito R; Miyauchi K; Yasuda S; Kaikita K; Akao M; Ako J; Matoba T; Nakamura M; Hagiwara N; Kimura K; Hirayama A; Matsui K; Ogawa H;
JAMA Cardiol; 2022 Aug; 7(8):787-794. PubMed ID: 35704345
[TBL] [Abstract][Full Text] [Related]
2. Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease.
Yasuda S; Kaikita K; Akao M; Ako J; Matoba T; Nakamura M; Miyauchi K; Hagiwara N; Kimura K; Hirayama A; Matsui K; Ogawa H;
N Engl J Med; 2019 Sep; 381(12):1103-1113. PubMed ID: 31475793
[TBL] [Abstract][Full Text] [Related]
3. Antithrombotic Therapy for Atrial Fibrillation and Coronary Artery Disease in Patients With Prior Atherothrombotic Disease: A Post Hoc Analysis of the AFIRE Trial.
Matsuzawa Y; Kimura K; Yasuda S; Kaikita K; Akao M; Ako J; Matoba T; Nakamura M; Miyauchi K; Hagiwara N; Hirayama A; Matsui K; Ogawa H;
J Am Heart Assoc; 2021 Nov; 10(21):e020907. PubMed ID: 34658247
[TBL] [Abstract][Full Text] [Related]
4. Bleeding and Subsequent Cardiovascular Events and Death in Atrial Fibrillation With Stable Coronary Artery Disease: Insights From the AFIRE Trial.
Kaikita K; Yasuda S; Akao M; Ako J; Matoba T; Nakamura M; Miyauchi K; Hagiwara N; Kimura K; Hirayama A; Matsui K; Ogawa H
Circ Cardiovasc Interv; 2021 Nov; 14(11):e010476. PubMed ID: 34474583
[TBL] [Abstract][Full Text] [Related]
5. Rivaroxaban monotherapy versus combination therapy according to patient risk of stroke and bleeding in atrial fibrillation and stable coronary disease: AFIRE trial subanalysis.
Akao M; Yasuda S; Kaikita K; Ako J; Matoba T; Nakamura M; Miyauchi K; Hagiwara N; Kimura K; Hirayama A; Matsui K; Ogawa H
Am Heart J; 2021 Jun; 236():59-68. PubMed ID: 33657403
[TBL] [Abstract][Full Text] [Related]
6. Rivaroxaban Monotherapy in Patients With Atrial Fibrillation After Coronary Stenting: Insights From the AFIRE Trial.
Matoba T; Yasuda S; Kaikita K; Akao M; Ako J; Nakamura M; Miyauchi K; Hagiwara N; Kimura K; Hirayama A; Matsui K; Ogawa H;
JACC Cardiovasc Interv; 2021 Nov; 14(21):2330-2340. PubMed ID: 34736731
[TBL] [Abstract][Full Text] [Related]
7. Atrial fibrillation and ischemic events with rivaroxaban in patients with stable coronary artery disease (AFIRE): Protocol for a multicenter, prospective, randomized, open-label, parallel group study.
Yasuda S; Kaikita K; Ogawa H; Akao M; Ako J; Matoba T; Nakamura M; Miyauchi K; Hagiwara N; Kimura K; Hirayama A; Matsui K
Int J Cardiol; 2018 Aug; 265():108-112. PubMed ID: 29764706
[TBL] [Abstract][Full Text] [Related]
8. Rivaroxaban Underdose for Atrial Fibrillation with Stable Coronary Disease: The AFIRE Trial Findings.
Arashi H; Yamaguchi J; Hagiwara N; Yasuda S; Kaikita K; Akao M; Ako J; Matoba T; Nakamura M; Miyauchi K; Kimura K; Hirayama A; Matsui K; Ogawa H;
Thromb Haemost; 2022 Sep; 122(9):1584-1593. PubMed ID: 35697255
[TBL] [Abstract][Full Text] [Related]
9. Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial.
Greenberg B; Neaton JD; Anker SD; Byra WM; Cleland JGF; Deng H; Fu M; La Police DA; Lam CSP; Mehra MR; Nessel CC; Spiro TE; van Veldhuisen DJ; Vanden Boom CM; Zannad F
JAMA Cardiol; 2019 Jun; 4(6):515-523. PubMed ID: 31017637
[TBL] [Abstract][Full Text] [Related]
10. Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the PIONEER AF-PCI Trial.
Kerneis M; Gibson CM; Chi G; Mehran R; AlKhalfan F; Talib U; Pahlavani S; Mir M; Bode C; Halperin JL; Nafee T; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Fox KAA; Cohen M
JACC Cardiovasc Interv; 2018 Apr; 11(7):626-634. PubMed ID: 29550085
[TBL] [Abstract][Full Text] [Related]
11. Antithrombotic therapy in atrial fibrillation patients with coronary artery disease: shifting paradigm to a "less is more" concept regimen.
Kawakami S; Yasuda S; Ogawa H
J Cardiol; 2020 Jul; 76(1):35-43. PubMed ID: 32389534
[TBL] [Abstract][Full Text] [Related]
12. Thrombocytopenia as a Bleeding Risk Factor in Atrial Fibrillation and Coronary Artery Disease: Insights From the AFIRE Study.
Iijima R; Tokue M; Nakamura M; Yasuda S; Kaikita K; Akao M; Ako J; Matoba T; Miyauchi K; Hagiwara N; Kimura K; Hirayama A; Matsui K; Ogawa H;
J Am Heart Assoc; 2023 Oct; 12(20):e031096. PubMed ID: 37815031
[TBL] [Abstract][Full Text] [Related]
13. A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial.
Mehra MR; Vaduganathan M; Fu M; Ferreira JP; Anker SD; Cleland JGF; Lam CSP; van Veldhuisen DJ; Byra WM; Spiro TE; Deng H; Zannad F; Greenberg B
Eur Heart J; 2019 Nov; 40(44):3593-3602. PubMed ID: 31461239
[TBL] [Abstract][Full Text] [Related]
14. Aspirin versus P2Y
Fukaya H; Ako J; Yasuda S; Kaikita K; Akao M; Matoba T; Nakamra M; Miyauchi K; Hagiwara N; Kimura K; Hirayama A; Matsui K; Ogawa H
Heart; 2021 Nov; 107(21):1731-1738. PubMed ID: 34261738
[TBL] [Abstract][Full Text] [Related]
15. Total bleeding with rivaroxaban versus warfarin in patients with atrial fibrillation receiving antiplatelet therapy after percutaneous coronary intervention.
Chi G; Yee MK; Kalayci A; Kerneis M; AlKhalfan F; Mehran R; Bode C; Halperin JL; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Cohen M; Peterson ED; Fox KAA; Gibson CM
J Thromb Thrombolysis; 2018 Oct; 46(3):346-350. PubMed ID: 29943350
[TBL] [Abstract][Full Text] [Related]
16. The impact of kidney function in patients on antithrombotic therapy: a post hoc subgroup analysis focusing on recurrent bleeding events from the AFIRE trial.
Matsui K; Yasuda S; Kaikita K; Akao M; Ako J; Matoba T; Nakamura M; Miyauchi K; Hagiwara N; Kimura K; Hirayama A; Ogawa H
BMC Med; 2022 Feb; 20(1):69. PubMed ID: 35209924
[TBL] [Abstract][Full Text] [Related]
17. Association of International Normalized Ratio Stability and Bleeding Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention.
Kerneis M; Yee MK; Mehran R; Nafee T; Bode C; Halperin JL; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Cohen M; Fox KAA; Gibson CM
Circ Cardiovasc Interv; 2019 Feb; 12(2):e007124. PubMed ID: 30704287
[TBL] [Abstract][Full Text] [Related]
18. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Connolly SJ; Eikelboom JW; Bosch J; Dagenais G; Dyal L; Lanas F; Metsarinne K; O'Donnell M; Dans AL; Ha JW; Parkhomenko AN; Avezum AA; Lonn E; Lisheng L; Torp-Pedersen C; Widimsky P; Maggioni AP; Felix C; Keltai K; Hori M; Yusoff K; Guzik TJ; Bhatt DL; Branch KRH; Cook Bruns N; Berkowitz SD; Anand SS; Varigos JD; Fox KAA; Yusuf S;
Lancet; 2018 Jan; 391(10117):205-218. PubMed ID: 29132879
[TBL] [Abstract][Full Text] [Related]
19. Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS.
Alexander JH; Wojdyla D; Vora AN; Thomas L; Granger CB; Goodman SG; Aronson R; Windecker S; Mehran R; Lopes RD
Circulation; 2020 May; 141(20):1618-1627. PubMed ID: 32223444
[TBL] [Abstract][Full Text] [Related]
20. Novel Oral Anticoagulant Based Versus Vitamin K Antagonist Based Double Therapy Among Stented Patients With Atrial Fibrillation: Insights From the PIONEER AF-PCI Trial.
Kerneis M; Yee MK; Mehran R; Nafee T; Bode C; Halperin JL; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Cohen M; Fox KAA; Gibson CM
Circ Cardiovasc Interv; 2019 Nov; 12(11):e008160. PubMed ID: 31707805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
